CANCER FIGHTERS OF HOUSTON
  • HOME
  • ABOUT
    • Our History
  • EVENTS
  • Get Involved
    • GRANTS
  • DONATE
  • CONTACT
  • Make A Donation

Cancer Research & Grant Recipients

Cancer Fighters works to fund research projects that are foundational and have great potential to treat cancer.
We consider projects that might not be funded otherwise because of the extensive competition for funds.
Picture
Guidelines for Research Committee

Specific areas we want addressed in the proposals are: explain the target cancer population, the rational for the proposal, the intervention proposed, how the money requested will be used, and the research application to treatment of other cancers, if any. 

Our target population is men, women, and children of all ages, and may include the underserved and underinsured population.
Who can make application? M.D.’s, Nurses, Public Health professional, PhD’s, Graduates or Student Graduates, maybe a starter in the field (in that case researcher needs to demonstrate he/she has professional mentorship and support) or is a researcher with lots of experience but is starting in a new area.


What outcome measures are we interested in?

• Laboratory focused research
• Clinical application as a focused goal or outcome
• Qualitative research or quantitative research


We want to continue to keep yearly awards open to consideration each year but may choose to focus on a particular area for a year. (Example: prostate, breast, kidney) This focus can be suggested by the Cancer Fighter Board or by the Research Committee. Our target area is Houston, Texas.

Require IRB (Internal Review Board) approval for research projects we fund. Cancer Fighters wants to request accountability and follow-up progress reports on the direct effect our seed grant money had for the researcher, education program or clinical program the grant funded. This can take the form of an annual written report. Grant money can be used to specifically fund employment, equipment, materials, and supplies.

CANCER FIGHTERS 2020 AWARDEE

DEVELOPING NEW STRATEGIES TO PREVENT AND TREAT MELANOMA METASTASES
The efficient development more effective treatments for brain metastases depends upon improving our understanding of the features that promote and sustain these tumors. Recently our lab conducted the first global analysis of the molecular features of melanoma brain metastases.Specifically, our studies showed that melanoma brain metastases upregulate oxidative phosphorylation, a metabolic pathway that generates energy and key molecules for cancer cell growth.  Importantly, our studies also showed that the tumor depend upon this pathway, as a small molecule inhibitor of oxidative phosphorylation prolonged the survival of mice with melanoma brain metastases.  These studies have shed new light on these tumors, and have identified aberrant tumor metabolism as a new player and therapeutic target in this disease. 
This proposal will build upon these initial findings to support the development of new strategies to prevent and treat brain metastases from melanoma.  First, we will determine if metabolic features of tumors can help to predict which melanoma patients are most likely to develop brain metastases.    Developing an improved understanding of the factors that predict risk of brain metastasis could have clinical impact through the development of evidence-based strategies for increased screening for high-risk patients.  The identification of molecular or immune factors that correlate with increased risk of brain metastasis may also suggest rational strategies to decrease their development.  Second, we will evaluate the efficacy and metabolic effects of different strategies to inhibit oxidative phosphorylation in melanoma brain metastases.  While our initial experiments with a direct inhibitor of oxidative phosphorylation confirmed the importance of this pathway, the drug used in those experiments can cause significant side effects. Fortunately, studies by our group and others have identified additional strategies that can inhibit oxidative phosphorylation in cancer cells which may be safer.  We will test if these new approaches are able to inhibit oxidative phosphorylation in melanoma brain metastases, if they can inhibit the growth of these tumors, and if they can help to overcome resistance to approved immune and targeted therapies for this disease. 
Together these experiments will help accelerate our research to prevent and control brain metastases from melanoma.  Importantly, our recent experiments suggest that some processes that promote the development and aggressiveness of brain metastases from melanoma may also play a role in brain metastases from other cancers as well, thus expanding the potential impact of these studies.  We also plan to leverage this generous donation toward the development of future funding applications, to further amplify the impact of this support.
​
Picture
​Michael A. Davies, MD, PhD, University of Texas MD Anderson Cancer Center
Brain metastases are a devastating and increasingly common complication of advanced cancer. For example, previous studies have shown that up to 60% of patients with metastatic melanoma, the most aggressive form of skin cancer, will be diagnosed with brain metastases during the course of their disease. Historically the average survival for melanoma patients with brain metastases was very short. However, recent, clinical trials with new immune and targeted therapies have demonstrated much more promising results. Despite these advances, most patients still fail to achieve durable control of brain metastases, and brain metastases remain a leading cause of morbidity and mortality in this disease. Thus, developing more effective strategies to prevent and treat brain metastases from melanoma remains a critical unmet need.

CANCER FIGHTERS 2019 AWARDEE

​DEPARTMENT OF GASTROENTEROLOGY HEPATOLOGY AND NUTRITION, DIVISION OF INTERNAL MEDICINE

Picture
MD Anderson – Dr. Yinghong Wang MD, PhD
The Target Cancer is colon cancer and side effects of cancer treatment.
Colitis is a devastating side effect of immune based colon cancer treatment and often results in stopping therapy to treat the cancer.  Restoring the health of the colon is important so cancer treatment can resume.
Restoring the fecal microbiome plays a critical role in normalizing colon function. This has been done successfully with fecal transplant therapy.  An article in Nature medical journal has been published for this novel idea. 
The study will Take 10 patients with colitis (IMC) to receive fecal transplant after colon cancer therapy is interrupted.  If fecal transplant is proven safe and effective then this ground breaking treatment to manage the side effect of IMC during colon cancer therapy.  Best scenario would be to include fecal transplant therapy via colonoscopy as a part of standard care associated with immunotherapy.
​

CANCER FIGHTERS 2018 AWARDEE

TEXAS A&M INSTITUTE OF BIOSCIENCES AND TECHNOLOGY

Picture

Dr. Yun Nancy Huang   2018 CFOH Seed Grant Research Recipient
My research interest is in understanding the role of DNA modifications in health and disease.  As I started my research program at Texas A&M University since July 2014, my laboratory has been focusing on elucidating the (patho)physiological functions of TET protein and its catalytic products in human cancers (Nat Genet 2016; Genome Biol 2016). My ongoing research directions include: (1) defining the dynamic changes of DNA modifications and their correlation with gene expression and transcriptional regulation; (2) delineating the regulatory network of DNA methylation/demethylation by using “omics” approaches to identify novel binding partners and complexes; (3) developing innovative (epi)genome-editing tools to alter aberrant DNA modifications implicated in cancer.

CANCER FIGHTERS 2017 AWARDEE

Picture
Samir "Sam" M. Hanash, MD, PhD
Dr. Hanash, professor of Clinical Cancer Prevention, was recruited to The University of Texas MD Anderson Cancer Center in July 2012 to lead the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer as director. He is a pioneer in cancer proteomics, a field aimed at identifying, among thousands of proteins, those that inform about cancer. He was the inaugural president of the Human Proteome Organization (HUPO) and a founder of the US Human Proteome Organization. In 2006, Nature Biotechnology listed Dr. Hanash among the world’s most influential leaders in biotechnology for his work in cancer proteomics.

MD ANDERSON CANCER CENTER

CANCER FIGHTERS 2016 AWARDEE

Picture
Stephanie A Pangas, Ph.D.
​
PROFESSIONAL STATEMENT
Twenty percent of women’s health problems worldwide are attributed to reproductive and sexual health issues. Disruptions in normal reproductive function cause health problems that extend beyond infertility, and include increases in cardiovascular disease, osteoporosis, and cognitive disorders. Furthermore, ovarian cancer is the most lethal gynecologic malignancy in women. In part, this is due to a lack of diagnostics needed for early detection. Therefore, the origin, diagnosis, and treatment of gynecological diseases are critical health issues that need to be addressed.
​

BAYLOR COLLEGE OF MEDICINE

CANCER FIGHTERS 2015 AWARDEE

Picture
Steven A. Curley, M.D
Dr. Steven A. Curley specializes in providing surgical care for patients with hepatobiliary and pancreatic malignancies. As our chief of surgical oncology and cancer center associate director, he leads efforts at Baylor College of Medicine (BCM) and on the McNair campus to build a world-class, multidisciplinary surgical oncology program with significant national and international outreach and stature.

Dr. Curley has been leading a basic sciences laboratory for 22 years. Currently, his research centers on the design, bench testing, and clinical study of novel noninvasive radiofrequency (RF) field treatment devices. Having developed two FDA-approved devices for invasive radiofrequency ablation needles to treat unresectable liver cancers, his current studies focus on targeted delivery of metallic or semiconducting nanoparticles that release heat under RF field induction to cause thermal cytotoxicity in cancer cells. His group has also performed complex physicochemical measurements of nanoparticles, and has conjugated them to antibodies, peptides, and pharmacologic agents to target cancer cells. He hopes to test these novel treatments in human clinical trials at BCM within the next two to three years, pending FDA approval.

WWW.BCM.EDU

CANCER FIGHTERS 2014 AWARDEE

Picture
Brendan Lee, M.D., Ph.D. 
Dr. Lee is Professor of Molecular & Human Genetics, Baylor College of Medicine Howard Hughes Medical Institute Investigator Director of the Rolanette and Berdon Lawrence Bone Disease Program of Texas. He is also founder and director of the Skeletal Dysplasia Clinic at Texas Children’s Hospital and founder and director of the Medical Student Research Track at Baylor College of Medicine. 
​As a pediatrician and geneticist, Dr. Lee studies structural birth defects and inborn errors of metabolism. Dr. Lee identified the first genetic causes of human skeletal dysplasias, birth defects that affect either the growth or strength of the skeleton. Most recently, he has studied the causes of brittle bone disease in children. In so doing, he is developing new approaches for diagnosing and treating these disorders. These conditions may present with hundreds of fractures at birth or isolated osteoporosis in children. 
​

Dr. Lee has received local and national recognition including induction into the American Association of Physicians, the American Society for Clinical Investigation, the Texas Academy of Medicine, Science, and Technology Edith and Peter O’Donnell Award in Medicine, the E. Meade Johnson Award for Pediatrics Research, the Michael E. DeBakey Excellence in Research Award, and the American Philosophical Society’s Judson Darland Prize for Patient-Oriented Clinical Investigation.
MD Anderson Seed Grants 

2007 Dr. Nicholas Vauthey - Dr. Vauthey’s grant was for $14,500. His findings were published in the Dec 4 issue of JAMA (Chun et al) and a paper by Blazer et al published in Journal of Clinical Oncology. Two of his fellows who worked on these papers were funded in part by Cancer Fighters of Houston. The information collected has directly influence patient treatment for colorectal cancer and decrease negative side effects and resulted in a pharmaceutical company grant of $200,000 which will fund the salary for 2 more research fellows.
2006 Dr. Patrick Hwu - States that many of our current treatments boosting the patients own immune system against multiple melanoma are the direct results of his teams’ research efforts and were initially funded by private donor sources included is $20,000 from Cancer Fighters. Please know that Cancer Fighters’ gift was put to excellent use, and may ultimately affect the lives of numerous patients and their families. Under these strained economic conditions, our support has allowed us to maintain forward momentum. Your investment in our program means a great deal to me, my faculty, and staff and has lead to larger funding of $8.6 million and several publications.
2006 Dr. Jeffrey Tarrand - Received $20,000 from Cancer Fighters to support the development of an innovative virus to kill pancreatic cancer.He used our funding to test the virus for negative side effects in a large animal study. With his excellent results he has now set up new lab specifically to develop the Reovirus and test it on mice with Leukemia and Pancreatic cancer.

Baylor College of Medicine Seed Grants

Dr. Xiao-Nan Li 2007 - Cancer Fighters helped him finalize an animal model that allowed him to do his research on brain cancer in children. Cancer Fighters awarded him $20,000.  Has received 2 grants as the lead investigator and received 2 additional grants as a co-investigator.  He is involved in 5 collaborative research projects using the mouse model with colleagues at Johns Hopkins University, Duke, Pittsburgh, U of Michigan, Wash U in Seattle, and one United Kingdom collaborative. He has published his results in the journal of STEM CELLS and gives Cancer Fighters acknowledgement for our funding.
Mike Lewis PhD 2008 - Dr. Lewis’ team was awarded $50,000 from Cancer Fighters to address treatment in late stage resistant breast cancers. Twelve papers were published in last year and 6 are in progress. The Breast Center at Baylor College of Medicine just received a treatment grant from the federal agency for $11.5 million which will be in collaboration with Methodist Hospital. 
Ching Lau, MD, PhD 2004-2005 - Cancer Fighters awarded two $45,000 awards to Dr. Lau. As a result of his research efforts he has received 9 major grants totalling about $7.2 million.  Two papers, one on bone tumor and the other one on brain tumor were published.  The Cancer Fighters' name is found in the acknowledgement section at the end of the papers.

Methodist Hospital Seed Grant

2008 Dr. Brian Butler - Drs. Brian E. Butler and John E. McGary at The Methodist Hospital have identified two types of sensors—superconducting quantum device magnetometers (SQUID) and Magnetoresistive (MR) a project recently funded by Cancer Fighters of Houston for $40,000. They found that both types of sensors have drawbacks that currently limit their effectiveness as affordable and reliable devices for tracking tumors in real-time. Drs. Butler and McGary now have a better understanding of localization accuracy, however, and are continuing to refine their research. I am excited to report that this project has already been accepted for publication in two journals:International Journal of Radiation Oncology*Biology*Physics and IEEE Transactions on Magnetics. 


​
Home
About
Contact
​
Grants
​Donations
​
Membership
​Events
© COPYRIGHT 2022 . ALL RIGHTS RESERVED.
  • HOME
  • ABOUT
    • Our History
  • EVENTS
  • Get Involved
    • GRANTS
  • DONATE
  • CONTACT
  • Make A Donation